Comparing the current results to its competitors, Generation Bio Co reported Revenue decrease in the 3 quarter 2025 year on year by -78.9 %, despite the revenue increase by the most of its competitors of 67.62 %, recorded in the same quarter.
Generation Bio Co 's Comment on Competition and Industry Peers
The company operates within the biotechnology and biopharmaceutical industry, which is characterized by rapid technological advancements, intense competition, and strong intellectual property protections. Its product candidates compete with existing and emerging therapies. The company’s technology and expertise in nucleic acid delivery are considered competitive advantages; however, it faces competition from major pharmaceutical and specialty pharmaceutical companies, biotechnology firms, academic institutions, governmental agencies, and research organizations. Specific competitors include AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., argenx SE, Arrowhead Pharmaceuticals, Inc., Capstan Therapeutics Inc., Hoffmann La Roche Ltd., Kymera Therapeutics, Inc., Moderna, Inc., Monte Rosa Therapeutics, Inc., Nurix Therapeutics, Inc., Orna Therapeutics, Inc., and Wave Life Sciences Ltd. Many of these competitors possess substantially greater financial, technical, and human resources, which may enhance their capabilities in research, development, and manufacturing.
May 9, 2024
The groundbreaking preclinical data on immunoquiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms unfolded at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting by the revolutionary biotechnology company, Generation Bio Co. Emphasizing its commitment to innovating genetic medicines, the company presented five substantial research posters related to its platforms and its enzymatic synthesis manufacturing procedure. In addition, an oral presentation outlining the innovation of its ctLNP platform was held.A Closer Look at Generation Bio s Research EndeavorsBased in Cambridge, Massachusetts, Generation Bio stands at the frontier of creating life-changing genetic therapi...
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
Rocket Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of gene therapies for rare and devastating diseases.
Portage Biotech Inc.'s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.
Sources:
Generation Bio Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Generation Bio Co versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
